AstraZeneca plc (LON: AZN) recently received a number of ratings updates from brokerages and research firms:

  • 8/9/2017 – AstraZeneca plc was upgraded by analysts at Investec from a “hold” rating to a “buy” rating. They now have a GBX 4,900 ($63.81) price target on the stock, down previously from GBX 5,000 ($65.11).
  • 8/9/2017 – AstraZeneca plc was given a new GBX 4,200 ($54.69) price target on by analysts at J P Morgan Chase & Co. They now have a “neutral” rating on the stock.
  • 8/8/2017 – AstraZeneca plc was given a new GBX 4,100 ($53.39) price target on by analysts at HSBC Holdings plc. They now have a “sell” rating on the stock.
  • 8/7/2017 – AstraZeneca plc had its “overweight” rating reaffirmed by analysts at Barclays PLC. They now have a GBX 5,500 ($71.62) price target on the stock.
  • 8/3/2017 – AstraZeneca plc had its price target lowered by analysts at Deutsche Bank AG from GBX 5,700 ($74.23) to GBX 5,300 ($69.02). They now have a “buy” rating on the stock.
  • 8/2/2017 – AstraZeneca plc had its “hold” rating reaffirmed by analysts at Shore Capital.
  • 8/2/2017 – AstraZeneca plc was given a new GBX 3,900 ($50.79) price target on by analysts at Goldman Sachs Group, Inc. (The). They now have a “sell” rating on the stock.
  • 8/2/2017 – AstraZeneca plc was given a new GBX 4,550 ($59.25) price target on by analysts at UBS AG. They now have a “neutral” rating on the stock.
  • 8/1/2017 – AstraZeneca plc had its price target lowered by analysts at Jefferies Group LLC from GBX 4,900 ($63.81) to GBX 4,400 ($57.30). They now have a “hold” rating on the stock.
  • 8/1/2017 – AstraZeneca plc had its “overweight” rating reaffirmed by analysts at Barclays PLC. They now have a GBX 5,500 ($71.62) price target on the stock.
  • 7/28/2017 – AstraZeneca plc was given a new GBX 5,200 ($67.72) price target on by analysts at Kepler Capital Markets. They now have a “buy” rating on the stock.
  • 7/28/2017 – AstraZeneca plc had its price target lowered by analysts at Credit Suisse Group from GBX 5,000 ($65.11) to GBX 4,700 ($61.21). They now have a “neutral” rating on the stock.
  • 7/28/2017 – AstraZeneca plc was downgraded by analysts at Beaufort Securities to a “sell” rating. They now have a GBX 3,900 ($50.79) price target on the stock.
  • 7/28/2017 – AstraZeneca plc was given a new GBX 5,500 ($71.62) price target on by analysts at Berenberg Bank. They now have a “buy” rating on the stock.
  • 7/28/2017 – AstraZeneca plc had its “buy” rating reaffirmed by analysts at Deutsche Bank AG. They now have a GBX 5,700 ($74.23) price target on the stock.
  • 7/28/2017 – AstraZeneca plc was downgraded by analysts at Morgan Stanley to an “equal weight” rating. They now have a GBX 4,700 ($61.21) price target on the stock, down previously from GBX 5,600 ($72.93).
  • 7/28/2017 – AstraZeneca plc had its “neutral” rating reaffirmed by analysts at J P Morgan Chase & Co. They now have a GBX 4,200 ($54.69) price target on the stock, down previously from GBX 5,000 ($65.11).
  • 7/28/2017 – AstraZeneca plc had its “buy” rating reaffirmed by analysts at Citigroup Inc.. They now have a GBX 6,000 ($78.14) price target on the stock.
  • 7/27/2017 – AstraZeneca plc was given a new GBX 4,500 ($58.60) price target on by analysts at S&P Global. They now have a “neutral” rating on the stock.
  • 7/27/2017 – AstraZeneca plc had its “hold” rating reaffirmed by analysts at Shore Capital.
  • 7/27/2017 – AstraZeneca plc had its “buy” rating reaffirmed by analysts at Liberum Capital. They now have a GBX 5,500 ($71.62) price target on the stock.
  • 7/27/2017 – AstraZeneca plc was given a new GBX 5,150 ($67.07) price target on by analysts at UBS AG. They now have a “neutral” rating on the stock.
  • 7/26/2017 – AstraZeneca plc had its “overweight” rating reaffirmed by analysts at Barclays PLC. They now have a GBX 6,300 ($82.04) price target on the stock.
  • 7/21/2017 – AstraZeneca plc had its “neutral” rating reaffirmed by analysts at BNP Paribas.
  • 7/21/2017 – AstraZeneca plc had its “neutral” rating reaffirmed by analysts at J P Morgan Chase & Co.
  • 7/14/2017 – AstraZeneca plc had its “sell” rating reaffirmed by analysts at Goldman Sachs Group, Inc. (The). They now have a GBX 3,900 ($50.79) price target on the stock.
  • 7/13/2017 – AstraZeneca plc had its “buy” rating reaffirmed by analysts at Kepler Capital Markets. They now have a GBX 5,500 ($71.62) price target on the stock.
  • 7/13/2017 – AstraZeneca plc had its “hold” rating reaffirmed by analysts at Shore Capital.
  • 7/13/2017 – AstraZeneca plc had its “buy” rating reaffirmed by analysts at Liberum Capital. They now have a GBX 5,500 ($71.62) price target on the stock.
  • 7/13/2017 – AstraZeneca plc had its “neutral” rating reaffirmed by analysts at J P Morgan Chase & Co.
  • 7/13/2017 – AstraZeneca plc had its “buy” rating reaffirmed by analysts at Citigroup Inc.. They now have a GBX 6,000 ($78.14) price target on the stock.
  • 7/12/2017 – AstraZeneca plc had its price target lowered by analysts at Jefferies Group LLC from GBX 5,500 ($71.62) to GBX 5,300 ($69.02). They now have a “hold” rating on the stock.
  • 7/5/2017 – AstraZeneca plc had its “buy” rating reaffirmed by analysts at Citigroup Inc..
  • 7/4/2017 – AstraZeneca plc was downgraded by analysts at HSBC Holdings plc to a “reduce” rating. They now have a GBX 4,500 ($58.60) price target on the stock.
  • 7/3/2017 – AstraZeneca plc had its price target raised by analysts at Barclays PLC from GBX 6,000 ($78.14) to GBX 6,300 ($82.04). They now have an “overweight” rating on the stock.
  • 6/30/2017 – AstraZeneca plc had its “buy” rating reaffirmed by analysts at Deutsche Bank AG. They now have a GBX 5,700 ($74.23) price target on the stock.
  • 6/27/2017 – AstraZeneca plc was given a new GBX 5,150 ($67.07) price target on by analysts at UBS AG. They now have a “neutral” rating on the stock.
  • 6/23/2017 – AstraZeneca plc had its “overweight” rating reaffirmed by analysts at Morgan Stanley. They now have a GBX 5,600 ($72.93) price target on the stock.
  • 6/21/2017 – AstraZeneca plc had its “hold” rating reaffirmed by analysts at Shore Capital.
  • 6/19/2017 – AstraZeneca plc had its “neutral” rating reaffirmed by analysts at Credit Suisse Group. They now have a GBX 5,000 ($65.11) price target on the stock.
  • 6/16/2017 – AstraZeneca plc had its price target raised by analysts at Jefferies Group LLC from GBX 5,000 ($65.11) to GBX 5,500 ($71.62). They now have a “hold” rating on the stock.
  • 6/16/2017 – AstraZeneca plc had its “buy” rating reaffirmed by analysts at Deutsche Bank AG. They now have a GBX 5,700 ($74.23) price target on the stock.
  • 6/15/2017 – AstraZeneca plc had its “hold” rating reaffirmed by analysts at Shore Capital.
  • 6/14/2017 – AstraZeneca plc had its “buy” rating reaffirmed by analysts at Liberum Capital. They now have a GBX 5,500 ($71.62) price target on the stock.

Shares of AstraZeneca plc (LON:AZN) opened at 4381.00 on Friday. AstraZeneca plc has a 1-year low of GBX 3,996.00 and a 1-year high of GBX 5,520.00. The company has a 50 day moving average of GBX 4,972.77 and a 200 day moving average of GBX 4,859.70. The company’s market cap is GBX 55.46 billion.

The business also recently announced a dividend, which will be paid on Monday, September 11th. Investors of record on Thursday, August 10th will be issued a dividend of GBX 68.90 ($0.90) per share. This represents a dividend yield of 1.35%. The ex-dividend date is Thursday, August 10th.

In related news, insider Nazneen Rahman bought 39 shares of AstraZeneca plc stock in a transaction that occurred on Thursday, July 27th. The stock was acquired at an average price of GBX 4,370 ($56.91) per share, with a total value of £1,704.30 ($2,219.43).

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.